New oral anticoagulants-TURKey (NOAC-TURK): Multicenter cross-sectional study

YILDIRIMTÜRK, Özlem; SİNAN, ÜMİT YAŞAR; GEDIKLI, Omer; Cakmak, Huseyin Altug; ÖZDEN, Özge; askin, lutfu; Altay, Servet; Besli, Feyzullah

New oral anticoagulants-TURKey (NOAC-TURK): Multicenter cross-sectional study

Servet ALTAY, (Trakya Üniversitesi, Tıp Fakültesi, Kardiyoloji Anabilim Dalı, Edirne, Türkiye)

Özlem YILDIRIMTÜRK, (Dr. Siyami Ersek Göğüs ve Kalp ve Damar Cerrahisi Eğitimi Ve Araştırma Hastanesi, Kardiyoloji Bölümü, İstanbul, Türkiye)

Hüseyin Altuğ ÇAKMAK, (Kaçkar Devlet Hastanesi, Kardiyoloji Bölümü, Rize, Türkiye)

Lütfü AŞKIN, (Palandöken Devlet Hastanesi, Kardiyoloji Anabilim Dalı, Erzurum, Türkiye)

Ümit Yaşar SİNAN, (İstanbul Üniversitesi, Kardiyoloji Enstitüsü, İstanbul, Türkiye)

Feyzullah BEŞLİ, (Harran Üniversitesi, Tıp Fakültesi, Kardiyoloji Anabilim Dalı, Şanlıurfa, Türkiye)

Ömer GEDİKLİ, (Ondokuz Mayıs Üniversitesi, Tıp Fakültesi, Kardiyoloji Anabilim Dalı, Samsun, Türkiye)

Özge ÖZDEN (Bakırköy Dr. Sadi Konuk Eğitim ve Araştırma Hastanesi, Kardiyoloji Kliniği, İstanbul, Türkiye)

The Anatolian Journal of Cardiology

17 1

Yıl: 2017 Cilt: 17 Sayı: 5 Sayfa Aralığı: 353 - 361 Metin Dili: İngilizce İndeks Tarihi: 29-07-2022

New oral anticoagulants-TURKey (NOAC-TURK): Multicenter cross-sectional study

Öz:

Objective: New oral anticoagulants (NOACs) are increasingly used both for prevention of stroke in non-valvular atrial fibrillation (NVAF) and the treatment of venous thromboembolism (VTE). In this study, we aimed to evaluate the current patterns of NOACs treatment in Turkey. Moreover, demographic and clinical parameters and bleeding and/or embolic events under NOACs treatment were analyzed.Methods: The New Oral Anticoagulants-TURKey (NOAC-TURK) study was designed as a multicenter cross-sectional study. A total of 2,862 patients from 21 different centers of Turkey under the treatment of NOACs for at least three months were included in this study. Demographic, clinical, and laboratory characteristics of study participants with their medications used were obtained through the NOAC-TURK survey database. Additional necessary medical records were obtained from electronic health records of participating centers.Results: Of the 2. 862 patients, 1.131 (39.5%) were male and the mean age was 70.3±10.2 years. Hypertension was found as the most frequent comorbidity (81%). The most common indication for NOACs was permanent atrial fibrillation (83.3%). NOACs were mainly preferred because of inadequate therapeutic range or overdose during warfarin usage. The most frequent complication was bleeding (n=217, 7.6%), and major bleeding was observed in 1.1% of the patients. Embolic events were observed in 37 patients (1.3%). Rivaroxaban and dabigatran were both more preferred than apixaban. Almost half of the patients (47.6%) were using lower doses of NOACs, which is definitely much more than expected.Conclusion: The NOAC-TURK study showed an important overview of the current NOACs treatment regimens in Turkey. Although embolic and bleeding complications were lower than or similar to previous studies, increased utilization of low-dose NOACs in this study should be considered carefully. According to the results of this study, NOACs treatment should be guided through CHADS-VASc and HASBLED scores to ensure more benefit and less adverse effects in NVAF patients.

Anahtar Kelime:

Konular: Kalp ve Kalp Damar Sistemi

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

Pistoia F, Sacco S, Tiseo C, Degan D, Ornello R, Carolei A. The epide- miology of atrial fibrillation and stroke. Cardiol Clin 2016;34:255-68.
Uyarel H, Onat A, Yüksel H, Can G, Ordu S, Dursunoğlu D. Incidence, prevalence and mortality estimates for chronic atrial fibrillation in Turkish adults. Arch Turk Soc Cardiol 2008; 36: 214-22.
Anderson FA Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Patward- han NA, Jovanovic B, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 1991; 151: 933-8.
Huang W, Goldberg RJ, Anderson FA, Kiefe CI, Spencer FA. Secu- lar trends in occurrence of acute venous thromboembolism: the Worcester VTE study (1985-2009) Am J Med 2014; 127: 829-39.e5.
Rothwell PM, Coull AJ, Giles MF, Howard SC, Silver LE, Bull LM, et al. Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK from 1981 to 2004 (Oxford Vascular Study). Lancet 2004; 363: 1925-33.
Koton S, Schneider AL, Rosamond WD, Shahar E, Sang Y, Gottes- man RF, et al. Stroke incidence and mortality trends in US communi- ties, 1987 to 2011. JAMA 2014; 312: 259-68.
Bassand JB, Accetta G, Camm AJ, Cools F, Fitzmaurice DA, Fox KAA, et al. Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. Eur Heart J 2016 Jun 29.
Başaran O, Beton O, Doğan V, Tekinalp M, Aykan AC, Kalaycıoğlu E, et al. ReAl-life Multicenter Survey Evaluating Stroke prevention strategies in non-valvular atrial fibrillation (RAMSES study). Anatol J Cardiol 2016; 16: 734-41.
Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clini- cal risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest 2010; 137: 263-72.
Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A nov- el user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138: 1093-100.
Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-70.
Schulman S, Kearon C. Subcommittee on Control of Anticoagula- tion of the Scientific and Standardization Committee of the Inter- national Society on Thombosis and Haemostasis. Definition of ma- jor bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3: 692-4.
Hosmer D, Lemeshow S, May S. Model Building Strategies and Methods for Logistic Regression. In: Hosmer D, editor. Applied Logistic Regression. 2nd ed. New Jersey: John Wiley & Sons, Inc. Canada; 2000. p.91-142.
Ertaş F, Kaya H, Yüksel M, Soydinç MS, Alan S, Ülgen MS. Atrial Fibrillation in Turkey: Epidemiologic Registry (AFTER) study design. Anatol J Cardiol 2013; 13: 339-43.
Lip GY, Laroche C, Dan GA, Santini M, Kalarus Z, Rasmussen LH, et al. A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EU- RObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. Europace 2014; 16: 308-19.
Proietti M, Laroche C, Opolski G, Maggioni AP, Boriani G, Lip GY; AF Gen Pilot Investigators. 'Real-world' atrial fibrillation management in Europe: observations from the 2-year follow-up of the EURObser- vational Research Programme-Atrial Fibrillation General Registry Pilot Phase. Europace 2016 May 18.
Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. and *the RE-LY Steering Committee and Investigators. Dab- igatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-51.
Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, and the ROCKET AF Steering Committee, for the ROCKET AF Investiga- tors. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-91.
Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al for the ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-92.
Larsen TB, Skjİth F, Nielsen PB, Kjældgaard JN, Lip GY. Compara- tive effectiveness and safety of non-vitamin K antagonist oral anti- coagulants and warfarin in patients with atrial fibrillation: propen- sity weighted nationwide cohort study. BMJ 2016 Jun 16; 353: i3189. doi: 10.1136/bmj.i3189.
Karacaglar E, Atar I, Yetis B, Corut H, Ersoy B, Yilmaz K, et al. The frequency of embolic risk factors and adequacy of anti-embolic treatment in patients with atrial fibrillation: A single tertiary center experience. Anatol J Cardiol 2012; 12: 384-90.
Ertas F, Duygu H, Acet H, Eren NK, Nazli C, Ergene AO. Oral antico- agulant use in patients with atrial fibrillation. Arch Turk Soc Cardiol 2009; 37: 161-7.

APA	Altay S, YILDIRIMTÜRK Ö, Cakmak H, askin l, SİNAN Ü, Besli F, GEDIKLI O, ÖZDEN Ö (2017). New oral anticoagulants-TURKey (NOAC-TURK): Multicenter cross-sectional study. , 353 - 361.
Chicago	Altay Servet,YILDIRIMTÜRK Özlem,Cakmak Huseyin Altug,askin lutfu,SİNAN ÜMİT YAŞAR,Besli Feyzullah,GEDIKLI Omer,ÖZDEN Özge New oral anticoagulants-TURKey (NOAC-TURK): Multicenter cross-sectional study. (2017): 353 - 361.
MLA	Altay Servet,YILDIRIMTÜRK Özlem,Cakmak Huseyin Altug,askin lutfu,SİNAN ÜMİT YAŞAR,Besli Feyzullah,GEDIKLI Omer,ÖZDEN Özge New oral anticoagulants-TURKey (NOAC-TURK): Multicenter cross-sectional study. , 2017, ss.353 - 361.
AMA	Altay S,YILDIRIMTÜRK Ö,Cakmak H,askin l,SİNAN Ü,Besli F,GEDIKLI O,ÖZDEN Ö New oral anticoagulants-TURKey (NOAC-TURK): Multicenter cross-sectional study. . 2017; 353 - 361.
Vancouver	Altay S,YILDIRIMTÜRK Ö,Cakmak H,askin l,SİNAN Ü,Besli F,GEDIKLI O,ÖZDEN Ö New oral anticoagulants-TURKey (NOAC-TURK): Multicenter cross-sectional study. . 2017; 353 - 361.
IEEE	Altay S,YILDIRIMTÜRK Ö,Cakmak H,askin l,SİNAN Ü,Besli F,GEDIKLI O,ÖZDEN Ö "New oral anticoagulants-TURKey (NOAC-TURK): Multicenter cross-sectional study." , ss.353 - 361, 2017.
ISNAD	Altay, Servet vd. "New oral anticoagulants-TURKey (NOAC-TURK): Multicenter cross-sectional study". (2017), 353-361.

APA	Altay S, YILDIRIMTÜRK Ö, Cakmak H, askin l, SİNAN Ü, Besli F, GEDIKLI O, ÖZDEN Ö (2017). New oral anticoagulants-TURKey (NOAC-TURK): Multicenter cross-sectional study. The Anatolian Journal of Cardiology, 17(5), 353 - 361.
Chicago	Altay Servet,YILDIRIMTÜRK Özlem,Cakmak Huseyin Altug,askin lutfu,SİNAN ÜMİT YAŞAR,Besli Feyzullah,GEDIKLI Omer,ÖZDEN Özge New oral anticoagulants-TURKey (NOAC-TURK): Multicenter cross-sectional study. The Anatolian Journal of Cardiology 17, no.5 (2017): 353 - 361.
MLA	Altay Servet,YILDIRIMTÜRK Özlem,Cakmak Huseyin Altug,askin lutfu,SİNAN ÜMİT YAŞAR,Besli Feyzullah,GEDIKLI Omer,ÖZDEN Özge New oral anticoagulants-TURKey (NOAC-TURK): Multicenter cross-sectional study. The Anatolian Journal of Cardiology, vol.17, no.5, 2017, ss.353 - 361.
AMA	Altay S,YILDIRIMTÜRK Ö,Cakmak H,askin l,SİNAN Ü,Besli F,GEDIKLI O,ÖZDEN Ö New oral anticoagulants-TURKey (NOAC-TURK): Multicenter cross-sectional study. The Anatolian Journal of Cardiology. 2017; 17(5): 353 - 361.
Vancouver	Altay S,YILDIRIMTÜRK Ö,Cakmak H,askin l,SİNAN Ü,Besli F,GEDIKLI O,ÖZDEN Ö New oral anticoagulants-TURKey (NOAC-TURK): Multicenter cross-sectional study. The Anatolian Journal of Cardiology. 2017; 17(5): 353 - 361.
IEEE	Altay S,YILDIRIMTÜRK Ö,Cakmak H,askin l,SİNAN Ü,Besli F,GEDIKLI O,ÖZDEN Ö "New oral anticoagulants-TURKey (NOAC-TURK): Multicenter cross-sectional study." The Anatolian Journal of Cardiology, 17, ss.353 - 361, 2017.
ISNAD	Altay, Servet vd. "New oral anticoagulants-TURKey (NOAC-TURK): Multicenter cross-sectional study". The Anatolian Journal of Cardiology 17/5 (2017), 353-361.